FDA Approves Rybrevant as First Targeted Treatment for Patients with NSCLC with EGFR Exon 20 Insertion Mutations
On May 21st, 2021, the Food and Drug Administration (FDA) approved Rybrevant (amivantamab-vmjw) for treatment of advanced non-small cell lung cancer (NSCLC) with a change in EGFR called exon 20 insertion. The FDA based their approval on the results of [...]